Seeing the brain differently
makes a world of difference

Learn More About Our Approach

News The latest from Sage

Press Releases

Sage Therapeutics Announces the New England Journal of Medicine Publishes Data from Phase 2 Trial with SAGE-217 in Major Depressive Disorder

Events

Sage FutureCast: An R&D and Portfolio Review

In the news

Learn more about the Sage Therapeutics Brand

See All News

Patients & Caregivers Putting patients and their families first

We are rethinking care and how it is delivered to help patients and families impacted by CNS disorders.

Postpartum Depression

Major Depressive Disorder

Patient Advocacy Programs

See Our Resources for Patients

Healthcare Providers It’s an exciting time in neuroscience

At Sage, our goal is to originate meaningfully differentiated drug candidates. We aim to transform the practice of medicine and rethink how CNS disorders are treated.

Learn More About Our Approach

Clinical Trials A distinct approach to neuroscience drug development

Sage is committed to developing new medicines to treat life-altering CNS disorders.

Learn More About Our Ongoing Clinical Trials

Pipeline Advancing a robust CNS clinical portfolio

We seek to make a positive impact on the unmet treatment needs of patients by advancing product candidates from a robust development pipeline of potential CNS therapeutics.

GABA
Compound
Indication
Preclinical
Phase 1
Phase 2
Phase 3
Registration
SAGE-217
Major Depressive Disorder
Compound: SAGE-217
Indicator: Major Depressive Disorder
SAGE-217
Postpartum Depression
Compound: SAGE-217
Indicator: Postpartum Depression
SAGE-217
Insomnia
Compound: SAGE-217
Indicator: Insomnia
SAGE-217
Bipolar Depression
Compound: SAGE-217
Indicator: Bipolar Depression
SAGE-324
Parkinson's Disease
Compound: SAGE-324
Indicator: Parkinson's Disease
SAGE-324
Essential Tremor
Compound: SAGE-324
Indicator: Essential Tremor
SAGE-324
Epileptiform Disorders
Compound: SAGE-324
Indicator: Epileptiform Disorders
NMDA
Compound
Indication
Preclinical
Phase 1
Phase 2
Phase 3
Registration
SAGE-718
NMDA Hypofunction
Compound: SAGE-718
Indicator: NMDA Hypofunction
Learn More About Our Programs and Research

Careers Rethinking CNS to make life better for patients and their families

Sage is a place where unconventional thinking to solve problems with new ideas is welcome - and where unconventional thinkers can imagine what's possible and do big.

Experience Our Culture